Sign In
Buy DGX
$233.72
+1.77 (+0.763%)
At Close: Aug 04, 2026
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
01:53pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down
06:56pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
01:40pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut
01:38pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.
Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down
01:37pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.
Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered
01:35pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.
10 defensive stocks that can also provide you with growth and dividends over the long term
10:05am, Wednesday, 10'th Aug 2022
The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
04:08pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
01:29pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
01:14pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat
04:29pm, Monday, 08'th Aug 2022 Zacks Investment Research
NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
01:33pm, Monday, 08'th Aug 2022 Zacks Investment Research
Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.
Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates
01:31pm, Monday, 08'th Aug 2022 Zacks Investment Research
Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
01:09pm, Monday, 08'th Aug 2022 Zacks Investment Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
04:58pm, Friday, 05'th Aug 2022 Zacks Investment Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
